Fructose drives de novo lipogenesis affecting metabolic health
Journal of Endocrinology · 08.02.2023 · 257 (2)
DOI: 10.1530/joe-22-0270 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, erschienen am 08.02.2023. Verfasst von Bettina Geidl-Flueck und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Switzerland. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite the existence of numerous studies supporting a pathological link between fructose consumption and the development of the metabolic syndrome and its sequelae, such as non-alcoholic fatty liver disease (NAFLD), this link remains a contentious issue. With this article, we shed a light on the impact of sugar/fructose intake on hepatic de novo lipogenesis (DNL), an outcome parameter known to be dysregulated in subjects with type 2 diabetes and/or NAFLD. In this review, we present findings from human intervention studies using physiological doses of sugar as well as mechanistic animal studies. There is evidence from both human and animal studies that fructose is a more potent inducer of hepatic lipogenesis than glucose. This is most likely due to the liver’s prominent physiological role in fructose metabolism, which may be disrupted under pathological conditions by increased hepatic expression of fructolytic and lipogenic enzymes. Increased DNL may not only contribute to ectopic fat deposition (i.e. in the liver), but it may also impair several metabolic processes through DNL-related fatty acids (e.g. beta-cell function, insulin secretion, or insulin sensitivity).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Switzerland.
ORCID-Profile: Philipp A Gerber
Zitieren
APA
Geidl-Flueck, B., & Gerber, P. A. (2023). Fructose drives de novo lipogenesis affecting metabolic health. Journal of Endocrinology, 257(2). https://doi.org/10.1530/joe-22-0270
Vancouver
Geidl-Flueck B, Gerber PA. Fructose drives de novo lipogenesis affecting metabolic health. Journal of Endocrinology. 2023;257(2). doi:10.1530/joe-22-0270
BibTeX
@article{GeidlFlueck2023,
author = {Geidl-Flueck, Bettina and Gerber, Philipp A},
title = {Fructose drives de novo lipogenesis affecting metabolic health},
journal = {Journal of Endocrinology},
year = {2023},
volume = {257},
number = {2},
doi = {10.1530/joe-22-0270}
}
EUVIMED